Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00

Key Points

• Cantor Fitzgerald raised InflaRx’s price target from $4.00 to $6.00 and maintained an “overweight” rating, implying potential upside of 248.84% from the prior close.
• Analyst sentiment is mixed but leans positive: InflaRx has a consensus “Moderate Buy” rating and an average price target of $7.33, with ratings ranging from Strong Buy to Sell.
• InflaRx reported quarterly EPS of $(0.11), missing the consensus estimate of $(0.07); shares opened at $1.72, while institutional investors own 42.39% of the company.

InflaRx (NASDAQ:IFRX - Get Free Report) had its price target hoisted by investment analysts at Cantor Fitzgerald from $4.00 to $6.00 in a report released on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Cantor Fitzgerald's price target would suggest a potential upside of 248.84% from the company's previous close.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded InflaRx from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Wednesday, June 24th. Oppenheimer initiated coverage on InflaRx in a research report on Friday, April 24th. They set an "outperform" rating and a $5.00 price objective on the stock. Zacks Research upgraded InflaRx from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 27th. Finally, HC Wainwright boosted their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, InflaRx has a consensus rating of "Moderate Buy" and an average price target of $7.33.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.72 on Friday. InflaRx has a 52-week low of $0.74 and a 52-week high of $2.95. The firm has a market capitalization of $124.34 million, a price-to-earnings ratio of -2.42 and a beta of 2.48. The stock has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.53.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Analysts forecast that InflaRx will post -0.29 earnings per share for the current year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Suvretta Capital Management LLC grew its stake in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company's stock worth $8,013,000 after buying an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC increased its position in InflaRx by 47.3% during the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company's stock valued at $3,348,000 after buying an additional 1,065,000 shares in the last quarter. Bank of America Corp DE purchased a new stake in InflaRx in the third quarter valued at about $3,316,000. Eversept Partners LP raised its stake in InflaRx by 1.5% in the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company's stock valued at $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in InflaRx in the first quarter worth about $766,000. Hedge funds and other institutional investors own 42.39% of the company's stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source